EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access · CC BY-NC-ND 4.0

Assessment of the Drug–Drug Interaction Potential of Lotiglipron (PF‐07081532) with Midazolam, Omeprazole, Dabigatran, Rosuvastatin, and the Oral Contraceptives Levonorgestrel and Ethinyl Estradiol

Carol Cronenberger, Neeta B Amin iD, Vu H Le, Santos Carvajal-Gonzalez, Amy L Ashworth, Ellen C Yi, Tilman Schuster, Yizhong Zhang, Robert C Frederich iD, Gary S Friedman, Ellen Q Wang, Nikolaos Tsamandouras

The Journal of Clinical Pharmacology · 2026-05 · 66 (5)

DOI: 10.1002/jcph.70158 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift The Journal of Clinical Pharmacology, online erschienen am 29.04.2026. Verfasst von Carol Cronenberger und 11 weiteren Autor:innen. Beteiligte Einrichtung: Pfizer Inc., Collegeville, PA, USA. Hauptthemen laut MEDLINE: Ethinyl Estradiol, Midazolam, Dabigatran, Levonorgestrel. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Two Phase 1 open‐label studies were conducted in otherwise healthy participants, with BMI classified as overweight/obesity, to assess the potential of lotiglipron (a glucagon‐like peptide‐1 receptor agonist) as precipitant for pharmacokinetic (PK) drug–drug interactions (DDIs) when co‐administered with substrates of cytochrome P450 (CYP) 3A (midazolam and oral contraceptive containing levonorgestrel/ethinyl estradiol [LE/EE]) and CYP2C19 (omeprazole) enzymes, and substrates of p‐glycoprotein (dabigatran), breast cancer resistance protein and organic anion transporting polypeptide transporters (rosuvastatin). Potential PK DDI between semaglutide and midazolam was also assessed. Co‐administration with lotiglipron led to modest dose‐dependent decreases in midazolam area under the concentration–time curve (AUC) (up to 30%), no clinically relevant changes in exposures of oral contraceptive (LE/EE), substantial reductions in omeprazole AUC (up to 70%) and clinically relevant increases in rosuvastatin AUC (up to 2.3‐fold). Upon co‐administration with lotiglipron, maximum observed plasma concentration (C max ) of dabigatran decreased (up to 55%) with no significant changes in AUC. No significant changes were observed in midazolam exposure (AUC inf and C max ) following co‐administration with semaglutide. Across both studies a subset of lotiglipron‐treated participants (31% and 19% in Studies 1 and 2, respectively) had elevations in liver transaminases (alanine/aspartate aminotransferase >3 × ULN), which (based on PK data) were associated with reduced ability of the liver to transport/metabolize drugs cleared by multiple pathways. Based on the results of the two Phase 1 studies reported here along with the results of a Phase 2 study where transaminases elevations were also noted, both Phase 1 studies were prematurely terminated along with the clinical development of lotiglipron. ClinicalTrials.gov identifiers : NCT05671653; NCT05788328.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ethinyl EstradiolMidazolamDabigatranLevonorgestrelRosuvastatin CalciumHumansDrug InteractionsFemaleAdultMaleYoung AdultSemaglutideMiddle AgedArea Under CurveCytochrome P-450 CYP3AGlucagon-Like PeptidesAdolescentContraceptives, OralDrug Combinations

Stichwörter der Autor:innen

Phase 1drug–drug interactionsglucagon‐like peptide‐1 receptor agonistlotiglipron

Substanzen

Ethinyl EstradiolMidazolamDabigatranLevonorgestrelRosuvastatin CalciumSemaglutideCytochrome P-450 CYP3AGlucagon-Like PeptidesContraceptives, OralDrug Combinations

Autor:innen und Institutionen

  • Pfizer Inc., Collegeville, PA, USA.
  • Pfizer Inc., Cambridge, MA, USA.
  • Pfizer Inc., New York, NY, USA.
  • Pfizer Inc., Walton Oaks, UK.
  • Pfizer Inc., Groton, CT, USA.

ORCID-Profile: Neeta B Amin, Robert C Frederich

Zitieren

APA

Cronenberger, C., Amin, N. B., Le, V. H., Carvajal-Gonzalez, S., Ashworth, A. L., Yi, E. C., Schuster, T., Zhang, Y., Frederich, R. C., Friedman, G. S., Wang, E. Q., & Tsamandouras, N. (2026). Assessment of the Drug–Drug Interaction Potential of Lotiglipron (PF‐07081532) with Midazolam, Omeprazole, Dabigatran, Rosuvastatin, and the Oral Contraceptives Levonorgestrel and Ethinyl Estradiol. The Journal of Clinical Pharmacology, 66(5). https://doi.org/10.1002/jcph.70158

Vancouver

Cronenberger C, Amin NB, Le VH, Carvajal-Gonzalez S, Ashworth AL, Yi EC, et al. Assessment of the Drug–Drug Interaction Potential of Lotiglipron (PF‐07081532) with Midazolam, Omeprazole, Dabigatran, Rosuvastatin, and the Oral Contraceptives Levonorgestrel and Ethinyl Estradiol. The Journal of Clinical Pharmacology. 2026;66(5). doi:10.1002/jcph.70158

BibTeX
@article{Cronenberger2026,
  author = {Cronenberger, Carol and Amin, Neeta B and Le, Vu H and Carvajal-Gonzalez, Santos and Ashworth, Amy L and Yi, Ellen C and Schuster, Tilman and Zhang, Yizhong and Frederich, Robert C and Friedman, Gary S and Wang, Ellen Q and Tsamandouras, Nikolaos},
  title = {Assessment of the Drug–Drug Interaction Potential of Lotiglipron (PF‐07081532) with Midazolam, Omeprazole, Dabigatran, Rosuvastatin, and the Oral Contraceptives Levonorgestrel and Ethinyl Estradiol},
  journal = {The Journal of Clinical Pharmacology},
  year = {2026},
  volume = {66},
  number = {5},
  doi = {10.1002/jcph.70158}
}
Kostenlos starten →